Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 66 articles: HTML format

Single Articles

May 2025
1. KIM EJ, Wang Y, Chen YL, Ma M, et al
   CARM1-mediated MAP2K4 methylation potentiates the oncogenic functions of MAP2K4 and constitutes a targetable dependency in triple-negative breast cancer.
   Cancer Res. 2025 May 29. doi: 10.1158/0008-5472.CAN-24-3476.
   PubMed     Abstract available
   
   
   
2. ELKHOLI IE, Robert A, Malouf C, Wu JL, et al
   Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation.
   Cancer Res. 2025 May 15:OF1-OF20. doi: 10.1158/0008-5472.CAN-23-2654.
   PubMed     Abstract available
   
   
   
3. GOHARI Z, Stojanovic L, Rassool FV
   Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer.
   Cancer Res. 2025;85:1747-1749.
   PubMed     Abstract available
   
   
   April 2025
4. LUTZ C, Chao X, de Klein B, Bhin J, et al
   Large-Scale Characterization of Orthotopic Cell Line-Derived Xenografts Identifies TGF-beta Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness.
   Cancer Res. 2025 Apr 30. doi: 10.1158/0008-5472.CAN-24-2022.
   PubMed     Abstract available
   
   
   
5. SOUTO EP, Gong P, Landua JD, Rajaram Srinivasan R, et al
   Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity.
   Cancer Res. 2025;85:1390-1409.
   PubMed     Abstract available
   
   
   
6. DOMMER AP, Kumarasamy V, Wang J, O'Connor TN, et al
   Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.
   Cancer Res. 2025;85:1310-1326.
   PubMed     Abstract available
   
   
   March 2025
7. PEDRETTI F, Abdalfttah M, Pellegrino B, Mateo F, et al
   Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer.
   Cancer Res. 2025 Mar 11. doi: 10.1158/0008-5472.CAN-24-2531.
   PubMed     Abstract available
   
   
   February 2025
8. SUN Z, Li Z, Wei Y, Xu L, et al
   SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression.
   Cancer Res. 2025 Feb 24. doi: 10.1158/0008-5472.CAN-24-2801.
   PubMed     Abstract available
   
   
   
9. BADO IL
   Deterministic Role of FOXF2 in Organ-Specific Macrometastasis Transition.
   Cancer Res. 2025;85:639-641.
   PubMed     Abstract available
   
   
   
10. ZHOU S, Zhang Y, Belmar J, Hou C, et al
    Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer.
    Cancer Res. 2025 Feb 12. doi: 10.1158/0008-5472.CAN-24-2492.
    PubMed     Abstract available
    
    
    
11. IPPOLITOV D, Lin YH, Spence J, Glogowska A, et al
    The Brain-Penetrant Pan ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases.
    Cancer Res. 2025 Feb 11. doi: 10.1158/0008-5472.CAN-24-1793.
    PubMed     Abstract available
    
    
    
12. METGE BJ, Williams L, Swain CA, Hinshaw DC, et al
    Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-24-0707.
    PubMed     Abstract available
    
    
    
13. MADORSKY ROWDO FP, Martini R, Ackermann SE, Tang CP, et al
    Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.
    Cancer Res. 2025;85:551-566.
    PubMed     Abstract available
    
    
    
14. TREMBATH HE, Spanheimer PM
    In Search of Representative Translational Cancer Model Systems.
    Cancer Res. 2025;85:407-409.
    PubMed     Abstract available
    
    
    January 2025
15. TABET I, Orhan E, Candiello E, Fenou L, et al
    Replication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection that Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1404.
    PubMed     Abstract available
    
    
    
16. VAN ALSTEN SC, Love MI, Calhoun BC, Butler EN, et al
    Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1788.
    PubMed     Abstract available
    
    
    
17. DEY P, Brisken C
    Breaking the Rhythm: Harnessing the Menstrual Cycle for Better Chemotherapy.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-25-0335.
    PubMed     Abstract available
    
    
    
18. VISAL TH, Bayraktar R, den Hollander P, Attathikhun MA, et al
    Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.
    Cancer Res. 2025 Jan 24:OF1-OF18. doi: 10.1158/0008-5472.CAN-24-0400.
    PubMed     Abstract available
    
    
    
19. PIERRO EW, Cottam MA, An H, Lehmann BD, et al
    Comparison of Lean, Obese, and Weight Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T Cell Populations.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-3511.
    PubMed     Abstract available
    
    
    
20. GAO L, Huang J, Xia J, Zhao P, et al
    SNHG17 Reprograms Energy Metabolism of Breast Cancer by Activating Mitochondrial DNAs Transcription.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-1271.
    PubMed     Abstract available
    
    
    
21. TAU S, Chamberlin MD, Yang H, Marotti JD, et al
    Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
    Cancer Res. 2025 Jan 9. doi: 10.1158/0008-5472.CAN-24-1204.
    PubMed     Abstract available
    
    
    December 2024
22. CHEN SY, He PL, Lu LY, Lin MC, et al
    ST6GAL1-Mediated Sialylation of PECAM-1 Promotes a Transcellular Diapedesis-Like Process that Directs Lung Tropism of Metastatic Breast Cancer.
    Cancer Res. 2024 Dec 30. doi: 10.1158/0008-5472.CAN-24-1550.
    PubMed     Abstract available
    
    
    
23. CHEN F, Ding K, Priedigkeit N, Elangovan A, et al
    Correction: Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
    Cancer Res. 2024;84:4298.
    PubMed    
    
    
    
24. FENG JR, Li X, Han C, Chang Y, et al
    C-Reactive Protein Induces Immunosuppression by Activating FcgammaR2B in Pulmonary Macrophages to Promote Lung Metastasis.
    Cancer Res. 2024;84:4184-4198.
    PubMed     Abstract available
    
    
    
25. SHI W, Li L, Zhao H, Li Z, et al
    Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma.
    Cancer Res. 2024;84:4156-4172.
    PubMed     Abstract available
    
    
    
26. BHAGWAT SV, Mur C, Vandekopple M, Zhao B, et al
    Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2608.
    PubMed     Abstract available
    
    
    
27. FRIELING JS, Lynch CC
    Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.
    Cancer Res. 2024;84:3917-3918.
    PubMed     Abstract available
    
    
    November 2024
28. JIANG WJ, Zhou TH, Huang HJ, Li LS, et al
    Breast Cancer Subtype-Specific Organotropism is Dictated by FOXF2-Regulated Metastatic Dormancy and Recovery.
    Cancer Res. 2024 Nov 26. doi: 10.1158/0008-5472.CAN-24-0479.
    PubMed     Abstract available
    
    
    
29. ZENG W, Zhang R, Huang P, Chen M, et al
    Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-1941.
    PubMed     Abstract available
    
    
    
30. SHEA A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, et al
    Modeling Drug Responses and Evolutionary Dynamics using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple Negative Breast Cancer.
    Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-1703.
    PubMed     Abstract available
    
    
    October 2024
31. KUETT L, Bollhagen A, Tietscher S, Sobottka B, et al
    Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes.
    Cancer Res. 2024 Oct 22. doi: 10.1158/0008-5472.CAN-24-1211.
    PubMed     Abstract available
    
    
    
32. CACKOWSKI FC, Korkaya H
    Breast Cancer Disseminated Tumor Cells: Do They Stay and Fight or Run and Hide?
    Cancer Res. 2024;84:3319-3321.
    PubMed     Abstract available
    
    
    
33. PAREJA F, Dopeso H, Wang YK, Gazzo AM, et al
    A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
    Cancer Res. 2024;84:3478-3489.
    PubMed     Abstract available
    
    
    
34. FALCONE M, Salhia B, Hughes Halbert C, Roussos Torres ET, et al
    Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.
    Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-1359.
    PubMed     Abstract available
    
    
    
35. GEMMA C, Lai CF, Singh AK, Belfiore A, et al
    Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
    Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-0013.
    PubMed     Abstract available
    
    
    
36. PURDY SC, Ford HL
    Remembering Hypoxia: Uncovering the Long-Term Effects of Transient Oxygen Deprivation on IFN Signaling and Progression of Breast Cancer.
    Cancer Res. 2024;84:3125-3127.
    PubMed     Abstract available
    
    
    
37. GONZALEZ ME, Brophy B, Eido A, Leonetti AE, et al
    CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/beta-Catenin Signaling to Inhibit EZH2-Driven EMT.
    Cancer Res. 2024;84:3235-3249.
    PubMed     Abstract available
    
    
    
38. SHIN SY, Chew NJ, Ghomlaghi M, Chueh AC, et al
    Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for FGFR4-Driven Cancers.
    Cancer Res. 2024;84:3296-3309.
    PubMed     Abstract available
    
    
    September 2024
39. KAUR J, Adhikari M, Sabol HM, Anloague A, et al
    Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis.
    Cancer Res. 2024 Sep 23. doi: 10.1158/0008-5472.CAN-24-0857.
    PubMed     Abstract available
    
    
    
40. LUO M, Shen N, Shang L, Fang Z, et al
    Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling.
    Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-0800.
    PubMed     Abstract available
    
    
    
41. GILKES DM, Chaturvedi P, Bajpai S, Wong CC, et al
    Retraction: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis.
    Cancer Res. 2024;84:2927.
    PubMed    
    
    
    
42. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    Retraction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
    Cancer Res. 2024;84:2926.
    PubMed    
    
    
    
43. CONNER SJ, Borges HB, Guarin JR, Gerton TJ, et al
    Obesity Induces Temporally Regulated Alterations in the Extracellular Matrix That Drive Breast Tumor Invasion and Metastasis.
    Cancer Res. 2024;84:2761-2775.
    PubMed     Abstract available
    
    
    August 2024
44. ZHOU Z, Si Y, Zhang J, Chen K, et al
    A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4099.
    PubMed     Abstract available
    
    
    
45. LI YW, Dai LJ, Wu XR, Zhao S, et al
    Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4066.
    PubMed     Abstract available
    
    
    
46. LEWIS MW, King CM, Wisniewska K, Regner MJ, et al
    CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-3995.
    PubMed     Abstract available
    
    
    
47. LI M, Lulla AR, Wang Y, Tsavachidis S, et al
    Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4130.
    PubMed     Abstract available
    
    
    
48. HEATH J, Mirabelli C, Annis MG, Sabourin V, et al
    The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple Negative Breast Cancer by Attenuating TGFbeta Signaling.
    Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-23-3887.
    PubMed     Abstract available
    
    
    
49. BUSHNELL GG, Sharma D, Wilmot HC, Zheng M, et al
    Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy.
    Cancer Res. 2024 Aug 6. doi: 10.1158/0008-5472.CAN-24-0030.
    PubMed     Abstract available
    
    
    July 2024
50. WANG X, Qu Y, Xu Q, Jiang Z, et al
    NQO1 Triggers Neutrophil Recruitment and NET formation to Drive Lung Metastasis of Invasive Breast Cancer.
    Cancer Res. 2024 Jul 29. doi: 10.1158/0008-5472.CAN-24-0291.
    PubMed     Abstract available
    
    
    
51. HSU WJ, Chiang MC, Chao YC, Chang YC, et al
    Arginine methylation of DDX3 by PRMT1 mediates mitochondrial homeostasis to promote breast cancer metastasis.
    Cancer Res. 2024 Jul 23. doi: 10.1158/0008-5472.CAN-23-3829.
    PubMed     Abstract available
    
    
    
52. PIEMONTE KM, Ingles NN, Weber Bonk KL, Valentine MJ, et al
    Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2558.
    PubMed     Abstract available
    
    
    
53. HUANG YZ, Sang MY, Xi PW, Xu RX, et al
    FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer.
    Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2738.
    PubMed     Abstract available
    
    
    
54. HILLIS AL, Martin TD, Manchester HE, Hogstrom J, et al
    Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-24-0970.
    PubMed     Abstract available
    
    
    
55. IRIONDO O, Mecenas D, Li Y, Chin CR, et al
    Hypoxic Memory Mediates Prolonged Tumor Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression.
    Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-23-2028.
    PubMed     Abstract available
    
    
    
56. LEE G, Wong C, Cho A, West JJ, et al
    E-cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer.
    Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-3082.
    PubMed     Abstract available
    
    
    June 2024
57. MENEGOLLO M, Bentham RB, Henriques T, Ng SQ, et al
    Multi-State Gene Cluster Switches Determine the Adaptive Mitochondrial And Metabolic Landscape of Breast Cancer.
    Cancer Res. 2024 Jun 26. doi: 10.1158/0008-5472.CAN-23-3172.
    PubMed     Abstract available
    
    
    
58. XU G, Huang R, Wumaier R, Lyu J, et al
    Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer.
    Cancer Res. 2024 Jun 20. doi: 10.1158/0008-5472.CAN-23-3998.
    PubMed     Abstract available
    
    
    
59. TUCKER JB, Carlsen CL, Scribano CM, Pattaswamy SM, et al
    CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3332.
    PubMed     Abstract available
    
    
    
60. SUN X, Verma SP, Jia G, Wang X, et al
    Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3854.
    PubMed     Abstract available
    
    
    
61. ELEMENTO O
    How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.
    Cancer Res. 2024;84:1745-1746.
    PubMed     Abstract available
    
    
    May 2024
62. HUANG MY, Hu SY, Dong J, Deng L, et al
    The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
    Cancer Res. 2024 May 15. doi: 10.1158/0008-5472.CAN-23-2781.
    PubMed     Abstract available
    
    
    April 2024
63. XIA J, Zhang L, Peng X, Tu J, et al
    IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429.
    PubMed     Abstract available
    
    
    
64. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    PubMed     Abstract available
    
    
    March 2024
65. ZHANG M, Zhou K, Wang Z, Liu T, et al
    A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
    Cancer Res. 2024 Mar 20. doi: 10.1158/0008-5472.CAN-23-2640.
    PubMed     Abstract available
    
    
    
66. QIU Y, Wang X, Sun Y, Jin T, et al
    ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
    Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.